Treating idiopathic pulmonary fibrosis: current opportunities and future challenges
Conflict of interest
Luca Richeldi reports receiving consulting fees from Boehringer Ingelheim, Intermune, Celgene, Sanofi, Anthera and Gilead; lecture fees from Intermune.
Luca Richeldi, MD, PhD, Center for Rare Lung Diseases, University Hospital of Modena, Via del Pozzo 71, 41124
Tel: +39 059 4222198
Fax: +39 059 4224231
No abstract is available for this article.